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In the 1970s, the late Judah Folkman postulated that tumors grow proportionately to their blood supply and that tumor
angiogenesis removed this limitation promoting growth and metastasis. Work over the past 40 years, varying from molecular
examination to clinical trials, veriﬁed this hypothesis and identiﬁed a host of therapeutic targets to limit tumor angiogenesis,
including the integrin family of extracellular matrix receptors. However, the propensity for some tumors to spread through
lymphatics suggests that lymphangiogenesis plays a similarly important role. Lymphangiogenesis inhibitors reduce lymph node
metastasis, the leading indicator of poor prognosis, whereas inducing lymphangiogenesis promotes lymph node metastasis even in
cancers not prone to lymphatic dissemination. Recent works highlight a role for integrins in lymphangiogenesis and suggest that
integrin inhibitors may serve as therapeutic targets to limit lymphangiogenesis and lymph node metastasis. This review discusses
the current literature on integrin-matrix interactions in lymphatic vessel development and lymphangiogenesis and highlights our
current knowledge on how speciﬁc integrins regulate tumor lymphangiogenesis.
1. Introductionto the LymphaticCirculation
Blood vessels supply tissues with nutrients and oxygen, re-
move waste products, and provide a mechanism for leuko-
cyte homing. Capillary exchange is vital for this process.
As blood pressure causes ﬂuid extravasation in the arterial
side of the capillary bed, colloid osmotic pressure drives
resorptionoftheﬂuidonthevenousside.However, ∼10%of
this ﬂuid is retained in the tissue accumulating as interstitial
ﬂuid[1].Duringinﬂammationandtumorigenesis,thisaccu-
mulation of interstitial ﬂuid is augmented due to enhanced
permeability of the capillaries resulting in tissue edema [2].
The lymphatic system regulates the transfer of interstitial
ﬂuid and cells from the tissue back into the circulation [1].
Nearly all vascularized tissues contain lymphatics with the
exception of the bone marrow, retina, and brain [3, 4].
Disrupting lymphatic vessel function, due to either primary
(genetic) or secondary (infectious, vessel damage) mech-
anisms, causes chronic tissue edema. In addition to ﬂuid
transport, the lymphatic circulation plays a vital role in
the inﬂammatory response. Antigen-presenting cells such
as macrophages and dendritic cells encounter antigen at
sites of local tissue inﬂammation. Endothelial cells in the
lymphatic capillaries produce CCL21 [5], a chemokine
that stimulates antigen-presenting cells to migrate into the
lymphatic capillaries [6]. Targeting to the lymphatics and
subsequently to the lymph nodes allows antigen-presenting
cells to interact with T cells and B cells, a key step in adaptive
immunity [7].
While similar in composition, lymphatic vessels and
blood vessels show some striking diﬀerences. Unlike the con-
tinuous vascular circulation, the lymphatic vessels are di-
vided into two distinct lymphatic trees (Figure 1(a)). Lym-
phatic vessels in the head, thorax, and right arm drain into
the right lymphatic trunk and empty into the right subcla-
vian vein. The lymphatics in the lower limbs, abdomen, and
left arm drain into the thoracic duct and empty into the left
subclavian vein [8]. Lymphatic capillaries are closed ended
tubesthatlackanormalsubendothelialbasementmembrane
a n ds h o wn os m o o t hm u s c l ec e l lo rp e ri c yt ec o v e r a g e[ 9, 10].
The material collected by these lymphatic capillaries, termed
lymph, is driven into the collecting lymphatic vessels by2 International Journal of Cell Biology
interstitial pressure. Collecting vessels resemble venous ves-
sels in that both have a subendothelial basement membrane,
smooth muscle cells, and bileaﬂet valves which prevent ﬂuid
backﬂow (Figure 1(b)). Intrinsic contractility of lymphatic
smooth muscle and skeletal muscle contractions propel the
lymph forward where it is eventually returned to the venous
circulation via the thoracic ducts [10]. Cell-cell junctions
of lymphatic endothelial cells (LECs) are discontinuous and
“button-like” allowing for a high degree of permeability in
these vessels [11, 12]. Elevated interstitial pressure creates
tension on LEC anchoring ﬁlaments enhancing LEC perme-
ability and interstitial ﬂuid uptake (Figure 1(c)).
2. Lymphangiogenesis inCancer
Metastatic tumor spread is responsible for more than 90%
of cancer mortality [32] and tumor access to blood and
lymphatic vessels drives systemic metastasis. For multiple
types of cancer, including melanoma and carcinoma of the
breast, cervix, colon, and prostate, lymph node metastasis
represents the ﬁrst step in tumor dissemination [10, 33, 34].
For this reason, the presence of lymph node metastasis
is a key determinant in tumor staging and the leading
indicator of poor prognosis [35, 36]. Lymphatic vessel
density (LVD), the product of both preexisting lymphatic
vessels and new vessels arising from lymphangiogenesis,
correlates with lymph node metastasis in a number of cancer
models [37]. As such, cancers arising in regions possessing
an already high LVD (e.g., tonsillar, tongue, head, and neck
cancer) may not require lymphangiogenesis for subsequent
lymph node metastasis [38]. In addition to vessel density,
the location of the lymphatic vessels may be critical as
intratumoral vessels have been reported as non-functional
based on high intratumoral interstitial ﬂuid pressures which
collapse lymphatics [39]. These results suggest peritumoral
lymphatics may serve as the primary site of lymphatic entry
for metastatic cells.
2.1. VEGF-C and Tumor Lymphangiogenesis. Multiple
growth factors modulate lymphangiogenesis, including he-
patocytegrowthfactor(HGF),platelet-derivedgrowthfactor
(PDGF), ﬁbroblast growth factor (FGF), angiopoietin-1, en-
dothelin-1, and members of the vascular endothelial cell
growth factor (VEGF) family [40–48]. Several VEGF iso-
forms mediate tumor angiogenesis and VEGF/VEGF-rece-
ptor interactions have been targeted to modulate angiogenic
responses [49]; the inhibitory anti-VEGF antibody Avastin
was the ﬁrst angiogenesis inhibitor to enter the market
in 2004. The VEGF-A/VEGF-R2 interaction drives blood
vessel angiogenesis, whereas lymphatic endothelial cells
also express VEGF-R3 which shows higher aﬃnity for
VEGF-D and fully processed VEGF-C isoforms [41, 50].
Overexpression of VEGF-C or VEGF-D in mouse xenograft
models enhances both lymphangiogenesis and lymph node
metastasis[10,51],andVEGF-Cexpressioninhumancancer
correlates with enhanced lymphangiogenesis, lymph node
metastasis, and poor prognosis (Figure 2(a)). Induction
of skin carcinogenesis in transgenic mice overexpressing
VEGF-C did not aﬀect primary tumor size, but enhanced
tumor metastasis to lymph nodes and the lung [52, 53].
Interestingly, VEGF-C overexpression enhanced lymph node
metastasis even in xenografts from tumors that do not
typically metastasize to lymph nodes [33, 51]. Perhaps
mostimportantly,inhibitorsofVEGF-C/VEGF-R3signaling,
including siRNA and soluble VEGF-R3, reduce lymphan-
giogenesis, lymph node metastasis, and enhance survival in
mouse tumor models [54–56].
2.2. Lymphangiogenesis Inhibitors. Angiogenesis regulation
involves the balance of proangiogenic and antiangiogenic
factors. While many stimuli are known to activate lym-
phangiogenesis, less data exists describing the presence
of endogenous lymphangiogenesis inhibitors (as has been
described for angiogenesis). Mice deﬁcient for the extra-
cellular matrix protein thrombospondin-1 (TSP1), the ﬁrst
described endogenous inhibitor of angiogenesis [57], show
exacerbated corneal lymphangiogenesis suggesting TSP1
may similarly inhibit lymphangiogenesis [58]. However,
TSP1 overexpression does not show a similar antilymphan-
giogenic eﬀect in skin carcinogenesis models presumably
due to the absence of TSP1’s antiangiogenic CD36 receptor
in lymphatic endothelial cells [59]. Despite this, TSP1 may
exert antilymphangiogenic activity indirectly by altering
the levels of other lymphangiogenesis eﬀectors. Consistent
with a mostly indirect eﬀect, the TSP1-activated growth
factor TGFβ actively suppresses lymphangiogenesis [60, 61],
and TSP1-mediated CD36 ligation on corneal macrophages
suppressedVEGF-CandVEGF-Dexpression[58].Vasohibin
and the collagen XVIII fragments endostatin and neostatin
7 reduce both angiogenesis and lymphangiogenesis [62–64],
suggesting that these inhibitors target pathways common to
both angiogenesis and lymphangiogenesis. Interestingly, a
splice variant of VEGF-R2 encoding for a soluble form of
the receptor did not aﬀect tumor angiogenesis but blocked
lymphangiogenesis presumably due to the ability of soluble
VEGF-R2 to bind VEGF-C [65].
2.3. Cancer Cell Chemotaxis toward Lymphatic Chemokines.
Cancer cells often enter lymphatics at the level of the lym-
phatic capillaries. This process is aided by the LECs them-
selves, which secrete chemokines such as CCL21 that induce
chemotaxis in antigen-presenting cells and some cancer cells
[5]. VEGF-C expressed by tumor cells and monocytes in
the tumor stroma stimulates LEC production of CCL21,
and CCL21 in turn activates its receptor CCR7 in can-
cer cells (Figure 2(b))[ 66]. Xenografts of CCR7 express-
ing melanoma cells were found to grow towards regions
of implanted LECs. Interestingly, only metastatic malignant
melanoma cells express CCR7, while their nonmalignant
counterparts do not [67, 68]. Similarly, breast cancer cells
showing lymph node metastasis also show enhanced CCR7
expression [69], and breast cancer cell xenografts showed
lymph node metastasis when CCR7 was expressed [70].
InadditiontotheCCL21/CCR7axis,lymphaticendothe-
lial cells also express SDF-1 which promotes metastasis to
lymph nodes in several cancer cells that express the SDF-1
receptor CXCR4 (For a full review see [71]). PDGF-DInternational Journal of Cell Biology 3
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Figure 1: Lymphatic system structure. (a) The lymphatic system is separated into two distinct sets of tubules. Lymphatic vessels drain
various areas of the body passing the material through a series of lymph nodes before returning the material to the venous circulation
through the thoracic ducts. (b) Lymphatic capillaries drain interstitial ﬂuid that accumulates during capillary exchange. The protein and
cell-rich ﬂuid termed lymph is then transported into vein-like valved collecting tubules. (c) Anchoring ﬁlaments couple lymphatic capillary
endothelial cells to the surrounding matrix. Forces applied through these anchoring ﬁlaments enhance lymphatic permeability to promote
tissue drainage.
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Figure 2: Local paracrine signaling controls lymphangiogenesis and lymph node metastasis. (a) Release of growth factors such as VEGF-C
and VEGF-D by tumor and stromal cells promotes lymphatic endothelial cell sprouting, invasion, and capillary tube formation. (b) VEGF-C
stimulates lymphatic endothelial cells to produce the chemokine CCL21. Expression of the CCL21 receptor on leukocytes and some tumor
cells stimulates chemotaxis toward the lymphatic vessel promoting lymphatic dissemination.4 International Journal of Cell Biology
overexpression stimulated CXCR4 expression in breast carci-
noma xenografts and promoted lymph node metastasis [72].
Furthermore, a polymorphism in SDF-1α (G801A) which
results in elevated SDF-1 expression was associated with
lymph node metastasis and shorter survival time in patients
with colorectal cancer [73].
3.TheIntegrinFamilyofReceptorsand
TheirExtracellularMatrixLigands
The extracellular matrix (ECM) is a highly organized com-
plex of collagens, proteoglycans, glycoproteins, and growth
factors capable of creating varying degrees of tissue tensile
strength, from mucosal linings to bones. Laminins and
collagen IV form a thin sheet-like matrix termed basement
membrane that separates epithelial and endothelial cells
from underlying connective tissue [74]. Fibrillar collagens
(e.g., collagen I, collagen III) make up the bulk of the body’s
connective tissue and play a major role in regulating tissue
tensile strength due to their capacity to be cross-linked into
ﬁbers. Although not normally involved in maintaining tissue
structure, provisional and matricellular matrix proteins
are rapidly deposited during tissue remodeling responses
coordinating cell migration and proliferation to heal injured
tissue. Provisional matrix proteins (e.g., ﬁbronectin, ﬁb-
rinogen, vitronectin) present in the bloodstream leak into
wounded areas and provide an adhesive scaﬀold for the
recruitment of cells [75, 76]. Matricellular matrix proteins
(e.g., thrombospondin, tenascin-C, SPARC, osteopontin)
generally play a minimal role in tissue structure but instead
regulate the cell’s interaction with structural matrix proteins
and modulate cell function [77, 78]. Interactions with ECM
proteins aﬀect nearly every aspect of cellular physiology,
from cell proliferation and migration, to gene expression
and diﬀerentiation [79]. Speciﬁc cell-matrix interactions are
critical for the survival of many cell types, and loss of
this adhesion dependence is a classic hallmark of neoplastic
change [80]. Furthermore, ECM proteins are secreted and
organized by the cells in the local environment, suggesting
that cells and their matrices exist in a state of “dynamic
reciprocity” as each one serves to regulate the other [81].
3.1. Matrix Composition in the Tumor Stroma. During tu-
morigenesis, the expanding tumor stimulates the produc-
tion of local supportive tissue termed the tumor “stroma”
which is composed of proliferating ﬁbroblasts, leukocytes,
blood and lymphatic vessels, and ECM proteins. Mounting
evidence suggests that the local tumor microenvironment
plays a critical role in cancer progression from a collection
of transformed cells to a clinically relevant disease [82].
During stromal matrix formation, cancer cells and stromal
ﬁbroblasts show enhanced deposition of ﬁbrillar collagens
(e.g., collagen I and III), provisional matrix proteins (e.g.,
ﬁbronectin), and matricellular proteins (e.g., tenascin-C,
osteopontin) [83, 84]. While the stromal matrix plays
established roles in angiogenesis and tumor metastasis [85],
mountingevidencesuggeststhatthestromalmatrixregulates
tumor lymphangiogenesis as well.
3.2. The Integrin Family of Matrix Receptors. Interactions
between ECM components and the integrin family of matrix
receptors serves to anchor cells to the underlying matrices,
mechanically couple the actin cytoskeleton to the external
environment, and activate a broad spectrum of integrin-
speciﬁc signaling pathways. The integrin family exists as
heterodimers of unique α and β subunits; mammals express
18 α and 8 β subunits forming 24 distinct αβ integrin
dimers(Figure 3(a)).Integrinexpressionpatternsdependon
the speciﬁc cell type and vary with environmental context
[86, 87]. Leukocyte homing responses typically involve a
separate subset of integrins (αLβ2, αMβ2, αXβ2, αDβ2)
that interact with counter-receptors on the endothelial cell
surface such as ICAM-1 and VCAM-1. Distinct collagen-
binding integrins (α1β1, α2β1, α10β1, α11β1) and laminin-
binding integrins (α3β1, α6β1, α6β4) serve to anchor
cells to the basement membrane and interstitial matrices.
Provisional matrix proteins often contain RGD sequences
that mediate interactions with α5β1, αvβ3, and αvβ5a m o n g
others. While the aﬃnity for an RGD sequence is a common
theme for provisional matrix binding integrins, there are
exceptionstothistrendsuchastherelatedintegrinsα4β1and
α9β1. The α4β1/α9β1 integrin subfamily interacts with both
components of the provisional matrix (e.g., ﬁbronectin CS-
1 and EDA domains, tenascin-C, osteopontin) and vascular
ligands involved in leukocyte homing (VCAM-1).
3.3.IntegrinSignaling. AscellscontacttheECM,theintegrin
extracellular domains bind to their ligands anchoring the cell
to the matrix and altering the integrin cytoplasmic domain
structure (Figure 3(b)). Structural proteins such as talin and
vinculin serve as bridges between the integrin cytoplasmic
tail and the actin cytoskeleton [88]. Although the integrin
cytoplasmic domain lacks intrinsic enzymatic activity, the
structural alteration assumed following integrin ligation
stimulates interactions with intracellular signaling proteins
[79, 89]. Integrin cytoplasmic domains diﬀer considerably
between individual integrin subunits allowing for integrin-
speciﬁc signaling responses, although some motifs are com-
mon [79, 90]. Ligated integrins recruit several nonreceptor
tyrosine kinases, including focal adhesion kinase (FAK),
integrin-linked kinase (ILK), and Src-family kinases, among
others[79,90].Integrinadhesionregulatessignalingthrough
the Rho family of small GTPases including Rac, cdc42,
and Rho resulting in cytoskeletal changes associated with
cell migration [91]. In addition, integrin signaling activates
multiple signaling pathways that aﬀect gene expression
patterns, such as the MAP kinases (ERK, JNK, and p38) and
the transcription factors c-fos, c-jun, and NF-κB[ 79].
4.CellMatrix Interactionsin
Lymphangiogenesis
4.1. Extracellular Matrix of the Tumor Stroma and Lym-
phangiogenesis. Although abundant in the tumor stroma,
collagen’s role in tumor lymphangiogenesis remains unclear.
A recently identiﬁed protein termed collagen and calcium-
binding EGF domain-1 (CCBE1) is essential for develop-
mental lymphangiogenesis in both zebraﬁsh and mouseInternational Journal of Cell Biology 5
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Figure 3: The integrin family of matrix receptors in lymphangiogenesis. (a) Integrin subunits divided by their binding partners (connecting
lines) and ligand-binding preferences (shaded areas). (b) Structure of integrin adhesions. Integrins link the extracellular matrix to the
intracellular actin cytoskeleton through structural adaptor proteins. Recruitment of signaling proteins activates pathways that regulate gene
expression (e.g., MAP kinases) and cytoskeletal reorganization (Rho GTPases). (c) Expression of the integrin α9β1 and its EDA-ﬁbronectin
ligand are required for proper lymphatic valve development. While α6β1a n dα9β1 are implicated in tumor angiogenesis, only α4β1h a s
been shown to be upregulated in lymphangiogenic vessels, to mediate LEC migration and tube formation in culture, and to be required for
tumor-associated lymphangiogenesis.
models [92, 93]. Although little is currently known about
CCBE1, it appears to bind to collagen and vitronectin in
the extracellular matrix, and a lack of CCBE1 expression
preventsthebuddingofnewlymphaticendothelialcellsfrom
the cardinal vein [93]. However, collagen’s role in mediating
thelymphangiogeniceﬀectsofCCBE1hasyettobeexplored.
While multiple provisional matrix and matricellular pro-
teins are implicated in tumor lymphangiogenesis, the most
convincing data for matrix-dependent lymphangiogenesis
involves the provisional matrix protein ﬁbronectin. The
ﬁbronectin gene can undergo alternative splicing to include
three additional sites: the connecting segment-1 (CS-1),
extra domain A (EDA), and extra domain B (EDB) [94].
Fibronectin in the tumor stroma often contains the CS-1
and EDA domains [95, 96]. Blocking antibodies against the
EDA site reduce LEC expression of Prox1 and F-actin, key
regulators of lymphangiogenesis [95]. In contrast to the CS-
1 and EDA domains, the EDB site in ﬁbronectin has not yet
been implicated in the lymphangiogenic process. In addi-
tion to ﬁbronectin, tenascin-C and osteopontin expression
in the tumor stroma is associated with enhanced lymph
node metastasis [97, 98], and LECs upregulate tenascin-C
expression during lymphangiogenesis [99]. Taken together,
these data show that the ECM composition in the tumor
stroma is a critical regulator of both lymphangiogenesis and
lymph node metastasis.
4.2.InteractionswithAnchoringFilamentsinLymphaticDeve-
lopment. Lymphatic capillary endothelial cells share some
similarities with vascular endothelial cells with the exception6 International Journal of Cell Biology
Table 1: Integrins in lymphangiogenesis.
LEC integrins Matrix ligands Data implicating integrin in lymphangiogenesis Current inhibitors FDA
approved or in clinical trials
α1β1, α2β1 Collagens
Overexpressed in LEC treated with VEGF-A [13]; blocking
antibodies reduce lymphangiogenesis in wound healing [13];
corneal inﬂammation models [14]
None
α5β1 Fibronectin Expressed in sprouting LECs [15]; small molecule inhibitors reduce
lymphangiogenesis in cornea [15]; lung inﬂammation models [16]
Volociximab
PF-04605412
JSM6427
[17–19]
αvβ3, αvβ5
Fibronectin (RGD),
Osteopontin,
Vitronectin,
Fibrinogen
Fibrillin
Minimal expression in LECs [20];
no role in lymphangiogenesis described to date [20, 21]
Cilengitide,
CNTO95
EMD525797
IMGN388
[17–19]
α9β1
Fibronectin (EDA),
Osteopontin,
Tenascin-C,
VEGF-A/C/D
Knockout mice die postnatally due to defective lymphatic valve
development (lung chylothorax) [22–24];
binds directly to VEGF-A/C/D and blocking antibodies inhibit LEC
migration [25, 26];
endostatin (α5β1a n dα9β1 inhibitor) blocks lymphangiogenesis in
cancer models [27, 28]
None
α4β1
Fibronectin (CS1),
Osteopontin,
Emillin-1
Not required for developmental lymphangiogenesis [29];
expressed in tumor-associated lymphangiogenic vessels and in
proliferating LECs [20, 29];
blocking antibodies prevent VEGF-C-induced LEC migration
[20, 29]; knockout and dominant negatives block tumor
lymphangiogenesis [29]
Natalizumab
Vedolizumab
ELND002
[17–19]
α6β1 Laminin,
Netrin-4
Mediates LEC adhesion and migration to prolymphangiogenic
factor Netrin-4 [30, 31]; colocalizes with netrin-4 in
lymphangiogenic vessels associated with breast tumor xenografts
[30]
None
of the absence of a continuous basement membrane and
surrounding pericytes. Instead of adhering to the basement
membrane, capillary LECs are attached to anchoring ﬁla-
ments composed of ﬁbrillin and emilin-1 which anchor the
lymphatic capillaries to the surrounding collagen ﬁlaments
in the interstitial matrix (Figure 1(c)) [100, 101]. This allows
for coupling of interstitial ﬂuid pressure changes to the
LEC cytoskeleton such that increased interstitial pressure
increasespermeabilityofthelymphaticcapillariestoenhance
drainage of interstitial ﬂuid. Lymphatic vessels express
multiple integrins including α1β1, α2β1, α3β1, α4β1, α5β1,
α6β1, αvβ3, and α9β1( Table 1)[ 13, 20, 30, 42, 102–104],
and LECs appear to utilize multiple integrins to interact with
these anchoring ﬁlaments. Fibrillin stimulates LEC adhesion
through the RGD-binding integrins α5β1a n dαvβ3[ 105].
However, the importance of α5β1a n dαvβ3t ol y m p h a t i c
endothelium is questionable, since mice deﬁcient for both
α5a n dαv integrin subunits in endothelial cells show no
apparent developmental defects in lymphangiogenesis or
lymphatic function [21]. Mutations in ﬁbrillin genes are
associated with Marfan’s syndrome, and ﬁbrillin knockout
mice recapitulate this phenotype [106]. However, no lym-
phatic phenotype has been described to date associated with
either Marfan’s syndrome or ﬁbrillin knockout mice. In
contrast, mice deﬁcient for the anchoring ﬁlament protein
emilin-1 show reduced numbers of anchoring ﬁlaments
[107], as well as hyperplastic and dysfunctional lymphatic
vessels. The integrin α4β1, classically associated with leuko-
cyte homing to regions of inﬂammation, is the only known
receptor for emilin-1 to date [108]. However, again, no
defects in developmental lymphangiogenesis were described
in mice lacking endothelial α4 integrins or expressing a
dominant negative form of α4 (Y991A) deﬁcient in talin and
paxillin binding [29].
4.3. Integrin α9β1 in Lymphatic Development. In contrast
to α4β1, α5β1, and αvβ3 integrins, the expression of α9β1
integrins in LECs is crucial to the process of developmental
lymphangiogenesis. The lymphatic network arises by the
initial segregation of a discrete endothelial cell population
from the cardinal vein [4]. This early transition from venous
endothelium to lymphatic endothelium is driven by the
homeobox transcription factor Prox1. Prox1 is required
for sprouting and migration of LECs toward lymphatic
growth factors, for example, VEGF-C and -D [109]. In
mouse embryos, Prox1 drives the expression of VEGFR3
and α9 integrin in the newly forming LECs [110]. Mice
deﬁcient for α9 integrin die postnatally due to lung chy-
lothorax, an accumulation of lymph in the pleural cavity
[22, 23]. Interestingly, a missense mutation in the humanInternational Journal of Cell Biology 7
α9 integrin gene is associated with congenital chylothorax
in human fetuses [24]. The extracellular matrix ligand
for α9β1 during lymphatic development remains unclear,
since multiple matrix proteins can interact with α9β1,
including tenascin-C, the EDA domain of ﬁbronectin, and
osteopontin (Figure 3(c)). However, ﬁbronectin appears to
be the dominant ligand for α9β1-dependent lymphatic valve
formation. EDA-positive ﬁbronectin deposition occurs early
during lymphatic valve formation in an α9β1 integrin-
dependent manner [22]. Mice deﬁcient in either α9β1
knockout or EDA-positive ﬁbronectin show similar defects
in lymphatic valve formation [22, 111]. Taken together, these
data illustrate a major role for α9β1 integrin and its matrix
ligand EDA-positive ﬁbronectin in lymphatic development.
4.4. Integrins in Inﬂammatory Lymphangiogenesis. Multiple
integrins have been implicated in pathological lymphan-
giogenesis. However, these studies are often limited to
a single model system providing little insight into their
relevance to tumor lymphangiogenesis. For example, VEGF-
A stimulates expression of the collagen-binding integrins
α1β1a n dα2β1i nL E C s[ 13], and blockade of these integrins
using antibodies prevents lymphangiogenesis in both wound
healing and corneal inﬂammation models [13, 14]. However,
the role of these integrins in tumor lymphangiogenesis has
not yet been addressed. The provisional matrix binding
integrins α5β1, αvβ3, and αvβ5 mediate tumor angiogen-
esis, and inhibitors to these integrins are currently being
tested in clinical trials [17–19]. However, the role these
integrins play in tumor lymphangiogenesis is less clear.
The ﬁbronectin-binding integrin α5β1 shows enhanced
expression in lymphatic sprouts [15], and ﬁbronectin can
induce LEC proliferation in culture [103]. Blocking the
α5β1 integrin with small molecule inhibitors JSM6427 and
JSM8757 signiﬁcantly blunts lymphangiogenesis in corneal
inﬂammation and airway inﬂammation models [15, 16].
Despite these ﬁndings, α5β1 does not appear to be involved
in tumor lymphangiogenesis [20]. Furthermore, αvβ3a n d
αvβ5 show only minimal expression in LECs and do
not appear to be involved in lymphangiogenic responses
[20].
4.5. α9β1a n dα4β1 Integrins Mediate Tumor Lymphangio-
genesis. Because α9β1 integrin has an established role in
developmental lymphangiogenesis, it likely also participates
in tumor angiogenesis as well, and several lines of evidence
support this. VEGF-C and VEGF-D are key mediators
of tumor lymphangiogenesis and α9β1 binds to the EYP
sequence in VEGF-A, C, and D to promote endothelial
and tumor cell migration [25, 26]. Consistent with this,
α9β1 blocking antibodies were shown to suppress VEGF-C-
inducedchemotaxisinLECs[26].Theangiogenicsuppressor
endostatin also reduces lymphangiogenesis in colorectal and
skin squamous cell carcinomas [27, 28] and inhibits lymph
node metastasis [27]. Interestingly, endostatin was recently
shown to block interactions between α9β1 and the EDA
domain of ﬁbronectin [28]. However, endostatin can also
inhibit ﬁbronectin interactions with α5β1[ 112], suggesting
that endostatin’s eﬀects may not be solely mediated by α9β1.
As such, no studies to date have deﬁnitively proven that
α9β1 plays a functional role in tumor lymphangiogenesis
in vivo.
While quiescent lymphatic endothelial cells weakly ex-
press α4β1, lymphatic vessels associated with variety of
human and murine tumors show enhanced α4β1 expression.
The lymphangiogenic/angiogenic growth factors VEGF-A,
VEGF-C, and bFGF all induce α4β1 expression in lymphan-
giogenic vessels, whereas proliferating LECs in vitro show
high levels of α4β1 expression [20, 29]. Both α4β1-blocking
antibodies and recombinant soluble VCAM-1 suppress lym-
phangiogenesis induced in VEGF-A or VEGF-C infused
matrigel plugs and lead to elevated LEC apoptosis [29].
Blocking antibodies to α4β1, but not α5β1, αvβ3, or αvβ5,
suppressed VEGF-C-induced LEC migration, matrigel inva-
sion, and tube formation (Figure 3(c)). Endothelial-speciﬁc
α4integrinknockoutmiceshowedsigniﬁcantlyreducedlym-
phangiogenesis in VEGF-C infused matrigel plugs. Mutating
the Y991A in the α4-cytoplasmic tail disrupts paxillin bind-
ing and inhibits leukocyte homing [113]. LECs isolated from
α4Y991AtransgenicmiceshowreducedmigrationtoVEGF-
C, and VEGF-C-induced lymphangiogenesis was reduced
in α4 Y991A transgenic mice [29]. Treatment with α4β1
blocking antibodies reduced lymphangiogenesis and lymph
node metastasis in implanted Lewis lung carcinoma and
B16 melanoma tumors. However, bone marrow transplant
experiments using wild-type and α4 Y991A knock-in mice
suggested that α4β1 inhibition in either recipient or donor
cells reduces lymphangiogenesis. Therefore, α4β1 inhibitors
may interfere with lymphangiogenesis by both inhibiting
LEC migration and preventing homing of proangiogenic
leukocytes [29].
Recent evidence suggests the laminin-binding integrin
α6β1 may play a role in tumor lymphangiogenesis as well.
The netrin family of axonal guidance molecules are secreted
laminin-like proteins implicated in angiogenesis and tumor
metastasis [114]. Lymphatic vessels associated with breast
tumors express netrin-4, and LECs show enhanced prolifera-
tion, migration, and tube formation in response to netrin-
4( Figure 3(c))[ 31]. Overexpression of netrin-4 increases
LVD in mouse skin, and breast cancer xenografts overex-
pressing netrin-4 show enhanced LVD and metastasis [31].
Netrin-4 binding to α6β1 cooperatively enhances binding
between α6β1 and laminin, suggesting netrin-4 directly
modulates α6β1a c t i v a t i o n[ 30]. Inhibition of α6β1 blocks
LEC migration on netrin-4, and α6β1c o l o c a l i z e sw i t h
netrin-4 in lymphatic vessels during embryogenesis, in adult
intestine, and in breast tumor xenografts [30]. However, a
direct causal role of α6β1 signaling in netrin-4-associated
lymphangiogenesis has yet to be determined.
5.ClinicalPerspective:
Targeting Lymphangiogenesis with
Integrin Inhibitors
Several integrin inhibitors have made their way into the
clinic, and a new wave of integrin inhibitors are advancing
through clinical trials (Table 1). Current integrin inhibitors8 International Journal of Cell Biology
fall into three categories: therapeutic antibodies, ligand-
mimetic peptides, and small molecule antagonists [17–19].
To date, the only FDA-approved integrin inhibitors have
targeted the integrin α4 (natalizumab) and platelet integrin
αIIbβ3 (abciximab, eptiﬁbatide, tiroﬁban) [18]. Most of
the inhibitors currently in clinical trials target the RGD-
binding integrins α5β1, αvβ3, αvβ5, and αIIbβ3w h i c hd o
not appear to signiﬁcantly modulate lymphatic function
[21]. The αvβ3/αvβ5 inhibitor cilengitide is the agent closest
to approval, with Phase III clinical trials for glioblastoma
ongoing. There are no current clinical trials speciﬁcally
testing the eﬃcacy of integrin inhibitors in lymphangio-
genesis and lymph node metastasis. Still, lymphangiogenesis
itself is only speciﬁcally targeted by a handful of trials, and
these tend to focus on the role of growth factor signaling
in lymphangiogenesis. While α9 is closely associated with
lymphatic development and LEC migration, the best data
for integrin involvement in lymphangiogenesis involves the
integrin α4β1[ 20, 29], and an inhibitor of the α4-integrin
natalizumab (Tysabri) has been approved for the treatment
of chronic inﬂammatory diseases such as multiple sclerosis
and Crohn’s disease since 2004 [115]. While this approval
was quickly recalled following multiple cases of progressive
multifocal leukoencephalopathy in a subset of patients, the
beneﬁts of natalizumab for multiple sclerosis patients were
found to outweigh the potential risks and the drug was again
approved for use in the USA in 2006 [116].
Targeting the α4β1a n dα9β1 integrins for therapeutic
r e d u c t i o ni nl y m p h a n g i o g e n e s i sw o u l db ep r e d i c t e dt or e -
duce inﬂammation in the tumor, as both α4β1a n dα9β1
are known to regulate leukocyte homing responses. How-
ever, the beneﬁts of this potential oﬀ target eﬀect are
unclear since inﬂammation plays a complex role in tumor
formation, progression, and metastasis [117, 118]. The
tumor stroma contains both tumor-associated macrophages
and lymphocytes. Tumor-associated macrophages, generally
alternatively activated M2 macrophages, produce a variety
of cytokines and growth factors that promote tumor growth
and reduce apoptosis [119]. Additionally, tumor-associated
macrophages promote tumor metastasis by enhancing ECM
degradation in the tumor stroma, promoting angiogenesis,
and stimulating endothelial adhesion molecule expression to
allow extravasation [117, 120]. As such, the presence of a
high number of tumor-associated macrophages is associated
with poor prognosis in multiple cancers [121]. Therefore,
integrin inhibitors that could restrict both inﬂammation
and lymphangiogenesis/lymph node metastasis may prove
beneﬁcial. Consistent with this, integrin α4β1 antagonists
suppressmacrophagecolonizationoftumorsandsubsequent
tumor angiogenesis [122]. Alternatively, adaptive immunity
plays a well-accepted role in immunosurveillance that is
thought to limit the growth of some tumors, including many
of those prone to lymph node metastasis such as colon
cancer and melanoma [118, 123]. In this case, inhibiting
α4β1a n dα9β1 might be expected to propagate tumor
formation. Therefore, diﬀerences in tumor type and stage,
immunogenicity, and tendency for lymph node metastasis
are likely to inﬂuence when and how α4β1a n dα9β1 integrin
inhibitors can be used in cancer therapy.
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